NEW YORK, Dec. 12, 2016 -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the American Depositary Shares (“ADSs”) of Teva Pharmaceutical Industries Limited (NYSE:TEVA) between February 10, 2015 and November 3, 2016, both dates inclusive (the “Class Period”). The lawsuit seeks to recover damages for Teva investors under the federal securities laws.
To join the Teva class action, go to http://www.rosenlegal.com/cases-979.html or call Phillip Kim, Esq. or Kevin Chan, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action.
NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE.
According to the lawsuit, throughout the Class Period Defendants made false and/or misleading statements and/or failed to disclose that: (1) Teva was engaging and/or had engaged in conduct that would result in an antitrust investigation by the U.S. Department of Justice (“DOJ”) and the State of Connecticut Office of the Attorney General; (2) the DOJ investigation and the underlying conduct could cause U.S. prosecutors to file criminal charges against Teva by the end of 2016 for suspected price collusion; (3) in turn, Teva lacked effective internal controls over financial reporting; and (4) as a result, Teva’s public statements were materially false and misleading at all relevant times.
A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than January 5, 2017. If you wish to join the litigation, go to: http://www.rosenlegal.com/cases-979.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim or Kevin Chan of Rosen Law Firm toll free at 866-767-3653 or via email at [email protected] or [email protected].
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm.
Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. Kevin Chan, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 34th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 [email protected] [email protected] [email protected] www.rosenlegal.com


Luxury Car Sales in the Middle East Take a Hit Amid Iran War
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports
Apple Turns 50: From Garage Startup to AI Crossroads
CTOC Adds 3,000 Doctors, 500 Hospitals Ahead of Liquidity Push
Russell 1000 Companies Hit $2.2T Cash Record While Aggressively Reinvesting in Growth
Jefferies Upgrades Sodexo to Buy With €55 Target After Historic CEO Appointment
Ukrainian Drones and the #MadeByHousewives Movement: Kyiv Fires Back at Rheinmetall CEO
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO
TSMC Japan's Second Fab to Produce 3nm Chips by 2028
KPMG UK Cuts 440 Audit Jobs Amid Low Attrition and Cooling Professional Services Demand
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire
Europe's Aviation Sector on Track to Meet 2025 Green Fuel Mandate
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit 



